AnaptysBio, Inc.
Every calculator, already run for ANAB
Open the full toolkit →You have the numbers on ANAB. Get the argument.
A written report on which of these readings actually decide the outcome for AnaptysBio, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering ANABAnalyst Price Target Disagreement for AnaptysBio, Inc.
Wall Street's bull case implies +154% from the current price; the bear case implies +27%. A 127% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ANAB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indicatio…
ANAB — frequently asked
Is ANAB a buy right now?
Wall Street's consensus rating on AnaptysBio, Inc. is Strong Buy across 8 analysts, with a mean price target of $89.63 (+62% vs. the current $55.20). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ANAB overvalued?
ANAB trades at — trailing earnings, against a DCF fair value of $11 per share. The current price implies 26% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ANAB's next earnings date?
AnaptysBio, Inc. is next scheduled to report earnings around Sep 21, 2026. A full ANAB research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for AnaptysBio, Inc.?
Analysts covering AnaptysBio, Inc. (ANAB) range from a bear-case target of $70.00 to a bull-case high of $140.00, with a mean consensus target of $89.63 across 8 analysts. The spread of $70.00 (127% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare AnaptysBio, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For AnaptysBio, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ANAB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on AnaptysBio, Inc., in minutes. 3 free reports included with every account — no credit card required.